The "Cancer Antibody Drug Conjugates Global Market Report 2025" has been added to ResearchAndMarkets.com's offering.

The global cancer antibody drug conjugates market is experiencing significant expansion, with a projected increase from $8.19 billion in 2024 to $9.17 billion in 2025, reflecting a compound annual growth rate (CAGR) of 11.9%. This growth has been fueled by the rising incidence of cancer globally, increased healthcare spending, demand for targeted treatments, and expanding oncology insurance coverage. The market's growth trend continues as it is anticipated to reach $14.17 billion by 2029, at a CAGR of 11.5%. Key drivers include the rising preference for personalized therapy, investments in oncology research, a focus on minimizing chemotherapy side effects, and penetration of specialized oncology clinics.

Prominent trends in the sector are marked by technological advancements in tumor-specific antibody targeting, innovations in payload delivery, companion diagnostics integration, bispecific antibody engineering, and research in immune-stimulating conjugates. The increasing cancer prevalence, driven by lifestyle risks such as poor diet and exposure to pollutants, is also boosting market growth. Antibody drug conjugates deliver chemotherapy drugs precisely to cancer cells, minimizing harm to healthy tissues while enhancing treatment effectiveness.

Leading companies, such as Daiichi Sankyo Co. Ltd., are focusing on advanced technologies like cleavable linker technology to improve targeted delivery and safety. In June 2025, Daiichi Sankyo received FDA approval for Datroway datopotamab deruxtecan dlnk, a TROP2-directed ADC for treating advanced or metastatic EGFR-mutated non-small cell lung cancer. These innovations underscore the promise of ADCs in precision medicine, improving drug delivery, and expanding treatment options for difficult-to-treat cancers.

The market dynamics are also shaped by significant corporate movements, such as Pfizer Inc.'s acquisition of Seagen Inc. for approximately $43 billion in December 2023. This acquisition enhances Pfizer's oncology capabilities by adding Seagen's ADC technology and cancer therapies to its portfolio. Such mergers and acquisitions reflect the industry's effort to enhance therapeutic reach and pipeline strength.

Major players in this market include Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Pfizer Inc., and AstraZeneca PLC. Geographically, North America led the market in 2024, with Asia-Pacific anticipated to be the fastest-growing region. Key markets covered include countries like the USA, China, India, and Germany.

The market outlook is being influenced by global trade relations and tariffs, affecting pharmaceutical companies' operations. These challenges have prompted a shift in API production and calls for trade exemptions. The cancer antibody drug conjugates report provides comprehensive market statistics, trends, and strategic insights necessary for stakeholders to navigate the changing landscape.

In summary, cancer antibody drug conjugates are gaining traction due to their precision in treating cancers, particularly those unresponsive to standard therapies. With ongoing R&D and strategic collaborations, the market is poised for robust growth, offering new therapeutic avenues for patients worldwide.

Report Scope

• Type of Antibody: Monoclonal, Bispecific, Low Molecular Weight, Polyclonal Antibodies
• Mechanism of Action: Cell Death Signal Inducers, Microtubule Disruptors, DNA Damage Inducers, Immune Checkpoint Inhibitors
• Technology: Cleavable Linker, Non-Cleavable Linker
• Disease Indication: Breast Cancer, Blood Cancers, Lung Cancer, Gastrointestinal Cancers, Prostate Cancer
• End-User: Hospitals, Specialty Clinics, Research Institutes

Subsegments:

• Monoclonal Antibodies: Fully Human, Humanized, Chimeric, Murine Monoclonal Antibodies
• Bispecific Antibodies: T Cell Engager, Dual Specific Antigen Targeting, Immune Checkpoint Modulating, Cytokine Redirecting
• Low Molecular Weight Antibodies: Single Chain Variable Fragment, Nanobody, Antibody Fragment, Domain Antibodies
• Polyclonal Antibodies: Purified, Recombinant, Animal-Derived, Human-Derived Polyclonal Antibodies

Key Attributes:

Companies Featured

• Johnson & Johnson
• Roche Holding AG
• Merck and Co. Inc.
• Pfizer Inc.
• AbbVie Inc.
• Bayer AG
• Sanofi S.A.
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• GlaxoSmithKline PLC
• Eli Lilly and Company
• Takeda Pharmaceutical Company Limited
• Amgen Inc.
• Gilead Sciences Inc.
• Astellas Pharma Inc.
• Daiichi Sankyo Company Limited
• Byondis BV
• Adienne Pharma and Biotech SA
• Helix BioPharma Corp.
• Adcytherix SAS

For more information about this report visit https://www.researchandmarkets.com/r/w5o2ta

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260114525581/en/